Rusdeep Mundae, None;
Linda Zangwill, Carl Zeiss Meditec Inc. (F), Carl Zeiss Meditec Inc. (R), Heidelberg Engineering GmbH (F), Optovue Inc. (F), Optovue Inc. (R), Quark (F), Topcon Medical Systems Inc. (F);
Sami Kabbara, None;
Naama Hammel, None;
Christopher Bowd, None;
Christopher Girkin, Carl Zeiss Meditech, Inc. (F), EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F);
Jeffrey Liebmann, Alcon, Inc (C), Allergan, Inc. (C), Bausch & Lomb, Inc. (C), Bausch & Lomb, Inc. (F), Carl Zeiss Meditech, Inc (C), Carl Zeiss Meditech, Inc (F), Diopysis, inc. (C), Diopysis, inc. (E), Diopysis, inc. (F), Heidelberg Engineering, GmbH (C), Heidelberg Engineering, GmbH (F), Merz Phamaceuticals, Inc (C), National Eye Institute (F), New York Glaucoma Research Institute (F), Optovue, inc (F), Quark Pharmaceuticals, Inc. (C), Reichert, Inc (C), Reichert, Inc (F), Sensimed, Inc. (C), Topcon, Inc. (F);
Felipe Medeiros, Alcon (C), Allergan (F), Allergan (C), Ametek (F), Ametek (C), Bausch+Lomb (F), Carl-Zeiss Meditec (F), Carl Zeiss Meditec Inc (R), Carl Zeiss Meditec Inc (C), Heidelberg Engineering (F), Heidelberg Engineering, GmbH (C), Topcon (F);
Robert Weinreb, Alcon, Inc (C), Allergan, Inc. (C), Bausch & Lomb, Inc. (C), Carl Zeiss Meditech, Inc. (C), Carl Zeiss Meditec Inc (F), Carl Zeiss Meditec Inc (R), Genentech (F), Heidelberg Engineering (F), Optovue (F), Topcon (C), Topcon (F);
Akram Belghith, None